Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
WBI-1001 is a synthetic,new, non-steroid, small molecule being developed as a candidate drug
for the topical, cream treatment of inflammatory skin diseases. As such, it affects T-cells
through inhibition of T-cell activities including their infiltration processes, and it shows
direct anti-inflammatory manifestation in the mouse edema model. This was a 28 day study
(plus one follow-up week) on patients with Atopic Dermatitis, and 36 patients were treated
randomly, BID with either 0.5%, 1.0% or placebo. Blood samples were taken weekly for PK
analysis.